BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 28116446)

  • 1. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
    Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
    Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
    Wurstbauer K; Deutschmann H; Dagn K; Kopp P; Zehentmayr F; Lamprecht B; Porsch P; Wegleitner B; Studnicka M; Sedlmayer F
    Radiat Oncol; 2013 Mar; 8():49. PubMed ID: 23497555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonresected non-small-cell lung cancer in Stages I through IIIB: accelerated, twice-daily, high-dose radiotherapy--a prospective Phase I/II trial with long-term follow-up.
    Wurstbauer K; Deutschmann H; Kopp P; Kranzinger M; Merz F; Nairz O; Studnicka M; Sedlmayer F
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1345-51. PubMed ID: 19910140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
    Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
    Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer : A retrospective study of elderly patients with stage III disease.
    Franceschini D; De Rose F; Cozzi L; Navarria P; Clerici E; Franzese C; Comito T; Tozzi A; Iftode C; D'Agostino G; Sorsetti M
    Strahlenther Onkol; 2017 May; 193(5):385-391. PubMed ID: 28168322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
    Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
    Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
    Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
    Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
    Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results.
    Graham MV; Pajak TE; Herskovic AM; Emami B; Perez CA
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):819-25. PubMed ID: 7860394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
    Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DART-bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily: high local control in early stage (I/II) non-small-cell lung cancer.
    Zehentmayr F; Wurstbauer K; Deutschmann H; Fussl C; Kopp P; Dagn K; Fastner G; Porsch P; Studnicka M; Sedlmayer F
    Strahlenther Onkol; 2015 Mar; 191(3):256-63. PubMed ID: 25245469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.
    Wurstbauer K; Weise H; Deutschmann H; Kopp P; Merz F; Studnicka M; Nairz O; Sedlmayer F
    Strahlenther Onkol; 2010 Oct; 186(10):551-7. PubMed ID: 20936459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
    Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.
    Maguire PD; Marks LB; Sibley GS; Herndon JE; Clough RW; Light KL; Hernando ML; Antoine PA; Anscher MS
    J Clin Oncol; 2001 Feb; 19(3):705-11. PubMed ID: 11157021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer.
    Ajlouni M; Chapman R; Kim JH
    Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction).
    Valeriani M; Marinelli L; Nicosia L; Reverberi C; De Sanctis V; Mollo D; Osti MF
    Radiol Med; 2019 Dec; 124(12):1324-1332. PubMed ID: 31317381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
    Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
    J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.